Intech Biopharm Corporation (TPEX:6461)
Taiwan
· Delayed Price · Currency is TWD 22.50
-0.05 (-0.22%)
Apr 2, 2025, 1:19 PM CST
Intech Biopharm Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -368.21 | -337.99 | -327.88 | -301.76 | -250.37 | Upgrade
|
| Depreciation & Amortization | 86.33 | 84.73 | 85.28 | 85.16 | 84.75 | Upgrade
|
| Other Amortization | 1.02 | 0.09 | 0.08 | 0.14 | 0.2 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.28 | 0.93 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.38 | -0.28 | -0.93 | -0.3 | - | Upgrade
|
| Stock-Based Compensation | 14.64 | 14.13 | 16.89 | 10.64 | 4.3 | Upgrade
|
| Other Operating Activities | 27.74 | 28.99 | 22.59 | 20.05 | 16.23 | Upgrade
|
| Change in Accounts Receivable | -6.15 | 0.56 | 11.38 | -10.28 | -1.5 | Upgrade
|
| Change in Inventory | -22.61 | 9.36 | 6.55 | -4.27 | -12.56 | Upgrade
|
| Change in Accounts Payable | 9.51 | -1.02 | -1.08 | 1.39 | 0.63 | Upgrade
|
| Change in Unearned Revenue | 5.83 | 2.58 | -0.69 | -2.21 | -0.17 | Upgrade
|
| Change in Other Net Operating Assets | -17.97 | -6.21 | -2.59 | 0.84 | -8.87 | Upgrade
|
| Operating Cash Flow | -269.22 | -204.13 | -190.39 | -200.61 | -167.38 | Upgrade
|
| Capital Expenditures | -43.62 | -30.04 | -10.74 | -21.31 | -48.16 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -0.17 | -0.26 | - | - | Upgrade
|
| Investment in Securities | 460 | -210 | -195 | -15 | 5 | Upgrade
|
| Other Investing Activities | 6 | 4.23 | 2.02 | 0.79 | 0.95 | Upgrade
|
| Investing Cash Flow | 422.37 | -235.98 | -203.98 | -35.52 | -42.21 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 30 | Upgrade
|
| Long-Term Debt Issued | 2.01 | 27 | 270 | - | 250 | Upgrade
|
| Total Debt Issued | 2.01 | 27 | 270 | - | 280 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -30 | - | Upgrade
|
| Long-Term Debt Repaid | -2 | -2 | -15.1 | - | -21.27 | Upgrade
|
| Total Debt Repaid | -2 | -2 | -15.1 | -30 | -21.27 | Upgrade
|
| Net Debt Issued (Repaid) | 0.01 | 25 | 254.9 | -30 | 258.73 | Upgrade
|
| Issuance of Common Stock | - | 460 | 5.06 | 300 | - | Upgrade
|
| Other Financing Activities | -32.44 | -31.98 | -21.26 | -18.08 | -16.6 | Upgrade
|
| Financing Cash Flow | -32.43 | 453.02 | 238.71 | 251.92 | 242.14 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.2 | 0 | -0 | -0 | 0.01 | Upgrade
|
| Net Cash Flow | 120.92 | 12.91 | -155.66 | 15.8 | 32.57 | Upgrade
|
| Free Cash Flow | -312.84 | -234.17 | -201.13 | -221.91 | -215.54 | Upgrade
|
| Free Cash Flow Margin | -786.44% | -905.98% | -850.56% | -570.48% | -1021.21% | Upgrade
|
| Free Cash Flow Per Share | -2.28 | -1.94 | -1.73 | -2.18 | -2.15 | Upgrade
|
| Cash Interest Paid | 32.51 | 32.18 | 21.68 | 18.2 | 16.6 | Upgrade
|
| Cash Income Tax Paid | 0.46 | 0.22 | 0.03 | -0 | -0.09 | Upgrade
|
| Levered Free Cash Flow | -206.2 | -150.09 | -108.35 | -137.16 | -137.77 | Upgrade
|
| Unlevered Free Cash Flow | -184.85 | -129.1 | -93.95 | -124.95 | -127.26 | Upgrade
|
| Change in Net Working Capital | 20.64 | -2.46 | -13.61 | 15.83 | 17.99 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.